UC scientist patented treatment for stubborn pathogens
There may be a solution on the horizon to combating superbug infections resistant to antibiotics. The tenacious bacteria and fungi sicken more than 2.8 million people and lead to more than 35,000 deaths in the United States each year.
An international team of researchers has found that a combination of ingredients (acidified nitrite and ethylenediaminetetraacetic acid) known as AB569 and developed by a University of Cincinnati scientist kills a bacteria (Pseudomonas aeruginosa), one of the most serious pathogens that exhibits multidrug resistance and virulence.
Their findings are available online in the scholarly journal of the Proceedings of the National Academy of Sciences of the United States of America.
“AB569 kills these pathogenic bacteria by targeting their DNA, RNA and protein biosynthesis as well as energy and iron metabolism at concentrations that do not harm human cells,” explains Daniel Hassett, a professor in the UC Department of Molecular Genetics, Biochemistry and Microbiology. “These were tested in laboratory mice with humanized cells. Our data implicate that AB569 is a safe and effective means that could be applied to eradicate these superbugs.”
Pseudomonas aeruginosa was applied to the lungs of laboratory mice for five days. This pathogen in humans causes pulmonary infections in patients with cystic fibrosis and chronic obstructive pulmonary disease and many other opportunistic infections. Pseudomonas aeruginosa is considered one of six ESKAPE pathogens, known by their acronym and considered among the most resistant and deadly to humans.
The ESKAPE pathogens include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These ESKAPE pathogens typically result in hospital-acquired infections leading to illness such as pneumonia and MRSA infections. Urinary tract infections that are resistant to antibiotics are also among illnesses caused by these organisms.
These superbugs have an ingenious mechanism of being able to resist traditional antibiotic therapies by a vast number of acquired strategies. Antibiotics affect specific processes in the bacteria, but not all of them. AB569 affects multiple processes at once leaving the exposed bacteria simply overwhelmed.
Daniel Hassett, professor UC College of Medicine
“These superbugs have an ingenious mechanism of being able to resist traditional antibiotic therapies by a vast number of acquired strategies,” explains Hassett, also the paper’s senior author. “Antibiotics affect specific processes in the bacteria, but not all of them. AB569 affects multiple processes at once leaving the exposed bacteria simply overwhelmed.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Speaker Amplifier Market to Reach $5.8 Bn, Globally, by 2027 at 7.6% CAGR: AMRon March 4, 2021 at 5:38 am
Allied Market Research published a report, titled, "Speaker Amplifier Market by Power (Low Power (Less Than 5W) and Mid Power (5W to 25W)), and End Use (Computer, Phones, Tablets, Over-Ear Headphones, ...
- Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AMLon March 4, 2021 at 5:38 am
GlycoMimetics today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or ...
- Schmeichel denies player power reportson February 25, 2021 at 4:00 pm
Leicester City goalkeeper Kasper Schmeichel has denied there was any player plot against Claudio Ranieri following his sacking this week. Ranieri was axed on Thursday only nine months after ...
- Into Recoveryon February 19, 2021 at 12:46 pm
Tom Niarhos, director of Al's Heart Warming Center in Pottstown, plays a voice message left for him by a guest who he was able to transition into a recovery house.
- Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trialon May 12, 2020 at 7:23 am
Continuing under development in the Arch portfolio are: AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung and wounds; and, 'Borg' peptide coatings that ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Study unravels antibiotic resistance in MRSA ‘superbug’ infectionson March 3, 2021 at 3:11 pm
An approach pioneered at UCLA predicts which methicillin-resistant Staphylococcus aureus infections are likely to be cured with antibiotic therapy.
- The Biden administration’s pandemic agenda must not ignore superbugson March 2, 2021 at 5:50 pm
Unless we leverage science and policy to fight antimicrobial resistance, the stage will be set for another global health crisis.
- Meet Australia's first homegrown, poo-loving superbugs that are cleaning Brisbane's sewageon March 1, 2021 at 12:28 pm
They're the poo-loving superbugs that are greening Queensland's sewage systems with their big appetite. Now a Brisbane wastewater plant has farmed enough Anammox bugs to fill 10 swimming pools.
- A Poo-Eating Superbug Has Been Grown Specially to Help Clean Aussie Sewage Wateron March 1, 2021 at 6:37 am
Locally grown superbugs that love feeding on nutrients found in poo have been introduced to a wastewater plant in Brisbane.
- A win against superbugson February 28, 2021 at 4:01 pm
Currently at least 700 000 people die annually due to drug resistant diseases ...